TREND Statement Checklist

Paper Section/ Topic	Item	Descriptor	Reported?	
	No		\checkmark	Pg #
Title and Abst	ract			
Title and Abstract	1	Information on how unit were allocated to interventions	у	3
		Structured abstract recommended	у	3
		Information on target population or study sample	у	3
Introduction				
Background	2	Scientific background and explanation of rationale	у	5,6
		Theories used in designing behavioral interventions	NA	
Methods			1	1
Participants	3	Eligibility criteria for participants, including criteria at different levels in		
· · · · · · · · · · · · · · · · · · ·		recruitment/sampling plan (e.g., cities, clinics, subjects)	у	7
		 Method of recruitment (e.g., referral, self-selection), including the 	,	
		sampling method if a systematic sampling plan was implemented	у	7
		Recruitment setting	y	7
		Settings and locations where the data were collected	y	9
Interventions	4	Details of the interventions intended for each study condition and how		
		and when they were actually administered, specifically including:		
		 Content: what was given? 	у	8
		 Delivery method: how was the content given? 	у	8
		 Unit of delivery: how were the subjects grouped during delivery? 	у	8
		 Deliverer: who delivered the intervention? 	у	7
		 Setting: where was the intervention delivered? 	у	7
		 Exposure quantity and duration: how many sessions or episodes or 		
		events were intended to be delivered? How long were they		
		intended to last?	У	8
		 Time span: how long was it intended to take to deliver the intervention to each unit? 		
		 o Activities to increase compliance or adherence (e.g., incentives) 	У	8
Objectives	5	 Activities to increase compliance or adherence (e.g., incentives) Specific objectives and hypotheses 	NA y	6
Outcomes	6	 Clearly defined primary and secondary outcome measures 	y y	9,10
Outcomes	0	 Methods used to collect data and any methods used to enhance the 	У	9,10
		quality of measurements	у	9,10
		 Information on validated instruments such as psychometric and biometric 		0,10
		properties	NA	
Sample Size	7	How sample size was determined and, when applicable, explanation of any		
·		interim analyses and stopping rules	NA	
Assignment	8	Unit of assignment (the unit being assigned to study condition, e.g.,		
Method		individual, group, community)	у	7
		Method used to assign units to study conditions, including details of any		
		restriction (e.g., blocking, stratification, minimization)	у	7
		• Inclusion of aspects employed to help minimize potential bias induced due		
		to non-randomization (e.g., matching)	у	16

TREND Statement Checklist

Blinding	9	• Whether or not participants, those administering the interventions, and		
(masking)	5	those assessing the outcomes were blinded to study condition assignment;		
(if so, statement regarding how the blinding was accomplished and how it		
		was assessed.		
			у	8
Unit of Analysis	10	Description of the smallest unit that is being analyzed to assess		
		intervention effects (e.g., individual, group, or community)	у	10
		• If the unit of analysis differs from the unit of assignment, the analytical		
		method used to account for this (e.g., adjusting the standard error		
		estimates by the design effect or using multilevel analysis)	NA	
Statistical Methods	11	• Statistical methods used to compare study groups for primary methods		
		outcome(s), including complex methods of correlated data	у	10
		• Statistical methods used for additional analyses, such as a subgroup		
		analyses and adjusted analysis	NA	
		Methods for imputing missing data, if used	NA	
		Statistical software or programs used	у	10
1			-	
Results				
Participant flow	12	• Flow of participants through each stage of the study: enrollment,		
		assignment, allocation, and intervention exposure, follow-up, analysis (a		
		diagram is strongly recommended)		
		 Enrollment: the numbers of participants screened for eligibility, 		
		found to be eligible or not eligible, declined to be enrolled, and		
		enrolled in the study	у	11
		 Assignment: the numbers of participants assigned to a study 		
		condition	у	11
		 Allocation and intervention exposure: the number of participants 		
		assigned to each study condition and the number of participants		
		who received each intervention	у	11
		 Follow-up: the number of participants who completed the follow- 		
		up or did not complete the follow-up (i.e., lost to follow-up), by		
		study condition	NA	
		 Analysis: the number of participants included in or excluded from 		
		the main analysis, by study condition	у	11
		• Description of protocol deviations from study as planned, along with		
		reasons	NA	
Recruitment	13	Dates defining the periods of recruitment and follow-up	у	7
Baseline Data	14	Baseline demographic and clinical characteristics of participants in each		
		study condition	у	11
		Baseline characteristics for each study condition relevant to specific		
		disease prevention research	NA	
		• Baseline comparisons of those lost to follow-up and those retained, overall		
		and by study condition	NA	
		Comparison between study population at baseline and target population		
		of interest	NA	
Baseline	15	• Data on study group equivalence at baseline and statistical methods used		
equivalence		to control for baseline differences		
			Ν	

TREND Statement Checklist

Numbers	16	• Number of participants (denominator) included in each analysis for each		
analyzed		study condition, particularly when the denominators change for different		
		outcomes; statement of the results in absolute numbers when feasible	у	11,12,13
		• Indication of whether the analysis strategy was "intention to treat" or, if		
		not, description of how non-compliers were treated in the analyses	NA	
Outcomes and estimation	17	• For each primary and secondary outcome, a summary of results for each estimation study condition, and the estimated effect size and a confidence interval to indicate the precision	NA	
		Inclusion of null and negative findings	у	12
		 Inclusion of results from testing pre-specified causal pathways through which the intervention was intended to operate, if any 	NA	
Ancillary	18	• Summary of other analyses performed, including subgroup or restricted		
analyses		analyses, indicating which are pre-specified or exploratory	NA	
Adverse events	19	• Summary of all important adverse events or unintended effects in each		
		study condition (including summary measures, effect size estimates, and		
		confidence intervals)	у	11
DISCUSSION				
DISCUSSION				
Interpretation	20	 Interpretation of the results, taking into account study hypotheses, 		
	20	 Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, 		
	20		у	15 to 19
	20	sources of potential bias, imprecision of measures, multiplicative analyses,	y	15 to 19
	20	sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study	y	15 to 19
	20	 sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study Discussion of results taking into account the mechanism by which the 	y y	15 to 19
	20	 sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative 		
	20	 sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations 		
	20	 sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations Discussion of the success of and barriers to implementing the intervention, 	у	17
	20	 sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations Discussion of the success of and barriers to implementing the intervention, fidelity of implementation 	y y	17
Interpretation		 sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations Discussion of the success of and barriers to implementing the intervention, fidelity of implementation Discussion of research, programmatic, or policy implications 	y y	17
Interpretation		 sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations Discussion of the success of and barriers to implementing the intervention, fidelity of implementation Discussion of research, programmatic, or policy implications Generalizability (external validity) of the trial findings, taking into account 	y y	17
Interpretation		 sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations Discussion of the success of and barriers to implementing the intervention, fidelity of implementation Discussion of research, programmatic, or policy implications Generalizability (external validity) of the trial findings, taking into account the study population, the characteristics of the intervention, length of 	y y	17
Interpretation		 sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations Discussion of the success of and barriers to implementing the intervention, fidelity of implementation Discussion of research, programmatic, or policy implications Generalizability (external validity) of the trial findings, taking into account the study population, the characteristics of the intervention, length of follow-up, incentives, compliance rates, specific sites/settings involved in 	у у у	17 18 18

From: Des Jarlais, D. C., Lyles, C., Crepaz, N., & the Trend Group (2004). Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. *American Journal of Public Health*, 94, 361-366. For more information, visit: <u>http://www.cdc.gov/trendstatement/</u>